FDA’s decision to grant accelerated approval to Sarepta’s DMD drug Exondys 51 (eteplirsen) has generated divergent opinions on what the approval means to the agency standards for approval and to the relationships between the different review levels within the Center for Drug Evaluation and Research.
Further coverage of those issues can be found in the sidebars, but behind them all is the important fundamental assessment...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?